New Zealand markets closed

CLLS Nov 2024 5.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.68000.0000 (0.00%)
As of 10:52AM EDT. Market open.
Full screen
Previous close2.6800
Open2.6800
Bid1.4000
Ask4.4000
Strike5.00
Expiry date2024-11-15
Day's range2.6800 - 2.6800
Contract rangeN/A
Volume1
Open interest20
  • GlobeNewswire

    Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

    NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a manuscript in Scientific Reports, demonstrating how three key factors can be determinant for efficient TALE base editing. TALE base editors are a recent and important addition to the gene editing landscape. By design, TALE

  • Zacks

    Cellectis (CLLS) Upgraded to Buy: Here's Why

    Cellectis (CLLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

  • Zacks

    After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS)

    The heavy selling pressure might have exhausted for Cellectis (CLLS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.